Showing results (1531-1540 of 3,353) with videos related to

Sort By:
Pageof 336
Pharmacoeconomics|November 12, 2024
Comparison of EQ-5D-Y-3L Utility Scores Using Nine Country-Specific Value Sets in Chinese AdolescentsYa'nan Wu, Yanjiao Xu, Zhao Shi, et al.
Pharmacoeconomics|August 7, 2024
Rethinking Tuberculosis Morbidity Quantification: A Systematic Review and Critical Appraisal of TB Disability Weights in Cost-Effectiveness AnalysesEwan M Tomeny, Thomas Hampton, Phuong Bich Tran, et al.
Pharmacoeconomics|August 2, 2024
Delay and Pay? Healthcare Costs Associated with Late Oral Anti-coagulant Prescribing in People with Atrial FibrillationRyan J Mulholland, Giorgio Ciminata, Terry J Quinn, et al.
Pharmacoeconomics|August 2, 2024
Estimation of Transition Probabilities from a Large Cohort (> 6000) of Australians Living with Multiple Sclerosis (MS) for Changing Disability Severity Classifications, MS Phenotype, and Disease-Modifying Therapy ClassificationsJulie A Campbell, Glen J Henson, Valery Fuh Ngwa, et al.
Pharmacoeconomics|July 3, 2024
Evaluating the Public Health and Health Economic Impacts of Baloxavir Marboxil and Oseltamivir for Influenza Pandemic Control in China: A Cost-Effectiveness Analysis Using a Linked Dynamic Transmission-Economic Evaluation ModelYawen Jiang, Jiaxin Wen, Jiatong Sun, et al.
Pharmacoeconomics|July 26, 2024
Systematic Review of Economic Evaluations of Systemic Treatments for Advanced and Metastatic Gastric CancerShikha Sharma, Niamh Carey, David McConnell, et al.
Pharmacoeconomics|October 19, 2023
Launch and Post-Launch Prices of Injectable Cancer Drugs in the US: Clinical Benefit, Innovation, Epidemiology, and CompetitionDaniel Tobias Michaeli, Thomas Michaeli
Pharmacoeconomics|March 29, 2024
Quality Appraisal in Systematic Literature Reviews of Studies Eliciting Health State Utility Values: Conceptual ConsiderationsMuchandifunga Trust Muchadeyi, Karla Hernandez-Villafuerte, Gian Luca Di Tanna, et al.
Pharmacoeconomics|August 18, 2023
Cost-Effectiveness Analysis of Pharmacogenomics (PGx)-Based Warfarin, Apixaban, and Rivaroxaban Versus Standard Warfarin for the Management of Atrial Fibrillation in Ontario, CanadaAneeka Hafeez, Lauren E Cipriano, Richard B Kim, et al.
Pharmacoeconomics|January 6, 2024
Cost Effectiveness of Zanubrutinib Versus Ibrutinib in Relapsed or Refractory Chronic Lymphocytic LeukemiaDong-Won Kang, Li Wang, Nicholas J Short, et al.
Pageof 336